Log In
Print this Print this

Ridinilazole (formerly SMT19969)

Also known as: SMT 19969

  Manage Alerts
Collapse Summary General Information
Company Summit Therapeutics plc
DescriptionOral small molecule heterocyclic antibiotic
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationClostridium
Indication DetailsTreat Clostridium difficile infection (CDI); Treat Clostridium difficile-associated diarrhea (CDAD)
Regulatory Designation U.S. - Fast Track (Treat Clostridium difficile infection (CDI));
U.S. - Qualified Infectious Disease Program (Treat Clostridium difficile infection (CDI))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today